Anavex Life Sciences Corp (AVXL)

[Investor2014]

It possible that the Anavex PLUS patent was a stop gap solution while other IP for A2-73 was in the process of being granted.

All the data presented so far says DZP makes little difference to the effectiveness of A2-73. Although DZP has some S1R binding the molecules are very different and A2-73 has allosteric binding i.e. not just to S1R and thus the two drugs likely have very different MOA, which is not entirely understood.